Alzheimer's disease - Where do we go from here?
Alzheimer's disease - Where do we go from here?
复制标题
DOI：
10.1016/j.bbrc.2022.08.075
复制
发表时间：
2022-12-10
影响因子：
3.1
通讯作者：
Bezprozvanny, Ilya
中科院分区：
文献类型：
--
作者：
Bezprozvanny, Ilya
这是阿尔茨海默病（AD）研究中一个非常令人困惑和具有挑战性的时期。在工业社会中，由于他汀类药物的引入和心血管疾病和中风风险的降低，预期寿命延长后，AD成为这些社会的主要问题。目前估计有650万65岁及以上的美国人患有AD，预计到2060年这一数字将增加到1385万[1]。AD目前是美国第六大死亡原因[2]。如此高的患者数量给美国社会带来了巨大的经济负担，到2022年，每年照顾这些患者的费用估计为3210亿美元，不包括非正式医疗服务的价值[2]。预计这一数字还将随着人口老龄化和AD患者数量的增加而增长。大多数其他工业化国家也面临类似的问题。在这种情况下，存在开发AD的疾病修饰治疗的巨大压力，政府和制药公司用于AD相关研究和药物发现的资金大量增加。然而，到目前为止，这些努力没有取得任何积极成果[3-5]。在这篇简短的文章中，我试图对这些努力进行批判性评估，并讨论该领域的潜在前进道路。我还必须说，我非常感谢有机会为《英国广播公司新闻》的这一期特刊撰稿。Ernesto邀请我写一篇关于钙离子失调在亨廷顿病中的作用的综述[6]，这对我进入神经变性领域起到了很大的作用，为此我真的很感谢他和BBRC。
This is a very confusing and challenging time in Alzheimer’s disease (AD) research. After life expectancy was extended in industrial societies due to introduction of statins and reduced risk of cardiovascular disease and stroke, AD become a major problem for these societies. Currently an estimated 6.5 million Americans age 65 and older are living with AD, and this number is projected to increase to 13.85 million in 2060 [1]. AD is currently the sixth leading cause of death in the United States [2]. Such high number of patients puts huge economic burden on USA society, with annual costs of caring for these patients in 2022 are estimated at $321 billion, not including the value of informal caregiving [2]. This number is also expected to grow with increase in aging population and number of AD patients. Most other industrialized countries face similar problems. In this situation there is an enormous pressure to develop disease-modifying treatment for AD, with large increase in funding for AD-related research and drug discovery by governments and pharmaceutical companies. However, so far these efforts unfortunately yielded little positive outcomes [3-5]. In this short article I attempt to provide critical evaluation of these efforts and discuss potential path forward for the field. I must also say that I am very grateful for the opportunity to contribute to this special issue of BBRC. Ernesto’s invitation to write a review on the role of Ca2+ dysregulation in Huntington’s disease [6] played a big role in my entry to the field of neurodegeneration and I am really thankful to him and BBRC for that.